TCG Crossover Management’s Structure Therapeutics GPCR Stock Holding History

TCG Crossover Management’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.77M	Sell	140,411 -780,446	-85%	-$53.4M	0.19%	44
2025 Q4	$64M	Sell	920,857 -142,143	-13%	-$5.8M	2.12%	15
2025 Q3	$29.8M	Hold	1,063,000	–	–	1.46%	20
2025 Q2	$22M	Hold	1,063,000	–	–	2.52%	19
2025 Q1	$18.4M	Hold	1,063,000	–	–	2.51%	18
2024 Q4	$28.8M	Hold	1,063,000	–	–	2.82%	15
2024 Q3	$46.7M	Buy	1,063,000 +368,453	+53%	+$14.2M	3.95%	11
2024 Q2	$27.3M	Sell	694,547 -903,874	-57%	-$37.1M	2.84%	14
2024 Q1	$68.5M	Sell	1,598,421 -511,163	-24%	-$21.6M	5.42%	5
2023 Q4	$86M	Buy	2,109,584 +606,837	+40%	+$34.8M	9.54%	1
2023 Q3	$75.8M	Buy	1,502,747 +1,152,747	+329%	+$37.1M	11.16%	1
2023 Q2	$14.5M	Hold	350,000	–	–	2.39%	13
2023 Q1	$8.33M	Buy	+350,000	New	+$8.22M	1.62%	17

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

TCG Crossover Management's GPCR Position: Q1 2026 in Review

TCG Crossover Management reduced its Structure Therapeutics (GPCR) stake by 85% in Q1 2026, selling an estimated $53.4M and leaving 140,411 shares worth $6.77M. The position accounts for 0.19% of the portfolio, ranked #44.

TCG Crossover Management first reported a position in GPCR in Q1 2023 and has held it in 13 quarters since. The position peaked at $86M in Q4 2023. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

TCG Crossover Management held 140,411 shares of Structure Therapeutics worth $6.77M as of Q1 2026.
TCG Crossover Management sold 780,446 Structure Therapeutics shares in Q1 2026, an estimated $53.4M.
Structure Therapeutics made up 0.19% of TCG Crossover Management's portfolio in Q1 2026, its #44 holding.
TCG Crossover Management first reported a position in Structure Therapeutics in Q1 2023 and has held it in 13 quarters since.
TCG Crossover Management's Structure Therapeutics position peaked at $86M in Q4 2023.
196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on TCG Crossover Management's 13F filing for Q1 2026, filed 15 May 2026.